Postoperative Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer
Hiromi Wada, Fumihiro Tanaka, Shigeki Hitomï
Abstract
Hiromi Wada, Fumihiro Tanaka, Shigeki Hitomï
Abstract
Given that no therapeutic methods of postoperative adjuvant chemotherapy for non-small-cell lung cancer have been established, we selected UFT (tegafur and uracil) for investigation because UFT is less injurious to the host
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Given that no therapeutic methods of postoperative adjuvant chemotherapy for non-small-cell lung cancer have been established, we selected UFT (tegafur and uracil) for investigation because UFT is less injurious to the host
Key concepts: Tegafur, Medicine, Chemotherapy, Adjuvant chemotherapy, Adjuvant, Lung cancer, Oncology, Internal medicine